Advertisement

Latest News

Invasive Treatment Options in Hypertrophic Cardiomyopathy

1 hour ago

Learn when cardiac myosin inhibitors suffice and when myectomy or alcohol ablation fits, with shared decisions at expert HCM centers.

Insights from the MAPLE Trial: Clinical Implications for oHCM Management

1 hour ago

MAPLE HCM reveals aficamten beats beta blockers in obstructive HCM, reshaping first-line therapy debates amid insurance hurdles.

Differentiating Cardiac Myosin Inhibitors: Clinical Considerations and Drug Interactions

1 hour ago

Explore how aficamten’s shorter half-life enables faster titration, flexible echo monitoring, and fewer drug interactions—making HCM treatment more patient-friendly and accessible.

Advancing Cardiac Myosin Inhibitor Therapy: Evidence, Monitoring, and Clinical Integration

1 hour ago

When beta blockers fall short in obstructive HCM, explore myosin inhibitors, disopyramide, or septal reduction—and see why patients breathe easier.

Patient Communication in Psoriasis Remission

1 hour ago

Ambitious psoriasis remission targets spark clinician debate, urging treatment tweaks to achieve sustained clearance, improve quality of life, and reduce comorbidity risks.

Advertisement
Advertisement